Bridge Bio Wins FDA Nod for Phase I/II Trial of NSCLC Treatment

Biotherapeutics has obtained approval for its investigational new drug (IND) plan to conduct the phase 1.2 clinical trial of the fourth-generation EGFR-mutant non-small cell lung cancer targeted agent, BBT-207, from the U.S. Food and Drug Administration.